Table 3. PEGylated Hemoglobin Oxygen Carriers.

Product Name	Manufacturer	Location of Clinical Use	FDA Approval Status	Current status
Hemospan	Sangart (San Diego, CA)	United States Europe	Not approved; reached phase III trials in Sweden and phase II trials in the United States	Last documented clinical trials in phase II in Australia and Brazil in 2013; not in clinical use as of 2019
Sanguinate	Prolong Pharmaceuticals (South Plainfield, NJ)	United States	Orphan drug designation from FDA	Used in patients with vaso-occlusive crisis of sickle cell disease